Study of ARQ 092 in Subjects With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC)
This is an open label, Phase 1/2 study of oral ARQ 092 (Miransertib) administered to subjects at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) (MOSAIC).
- Ages Eligible for Study: 2 – 21 years old
- Sexes Eligible for Study: All
Detailed inclusion and exclusion criteria as listed on clinicaltrials.gov